Results 1 to 10 of about 44,548 (260)

Nanopore sequencing for the screening of myeloid and lymphoid neoplasms with eosinophilia and rearrangement of PDGFRα, PDGFRβ, FGFR1 or PCM1-JAK2

open access: yesBiomarker Research, 2021
Eosinophilia represents a group of diseases with heterogeneous pathobiology and clinical phenotypes. Among the alterations found in primary Eosinophilia, gene fusions involving PDGFRα, PDGFRβ, FGFR1 or JAK2 represent the biomarkers of WHO-defined ...
Simone Romagnoli   +11 more
doaj   +1 more source

JAK2V617F variant allele frequency >50% identifies patients with polycythemia vera at high risk for venous thrombosis

open access: yesBlood Cancer Journal, 2021
Arterial (AT) and venous (VT) thrombotic events are the most common complications in patients with polycythemia vera (PV) and are the leading causes of morbidity and mortality.
Paola Guglielmelli   +15 more
doaj   +1 more source

Benefit-risk profile of cytoreductive drugs along with antiplatelet and antithrombotic therapy after transient ischemic attack or ischemic stroke in myeloproliferative neoplasms [PDF]

open access: yes, 2018
We analyzed 597 patients with myeloproliferative neoplasms (MPN) who presented transient ischemic attacks (TIA, n = 270) or ischemic stroke (IS, n = 327). Treatment included aspirin, oral anticoagulants, and cytoreductive drugs.
Arellano-Rodrigo, Eduardo   +41 more
core   +5 more sources

Differential Diagnoses of Systemic Mastocytosis in Routinely Processed Bone Marrow Biopsy Specimens: A Review [PDF]

open access: yes, 2010
Diagnosis of systemic mastocytosis (SM) is mainly based on the morphological demonstration of compact mast cell infiltrates in various tissue sites. In almost all patients such infiltrates are detected in the bone marrow.
Horny, H. -P., Sotlar, K., Valent, P.
core   +1 more source

Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms [PDF]

open access: yes, 2015
Clonal proliferation in myeloproliferative neoplasms (MPN) is driven by somatic mutations in JAK2, CALR or MPL, but the contribution of inherited factors is poorly characterized. Using a three-stage genome-wide association study of 3,437 MPN cases and 10,
Aranaz, P.   +99 more
core   +5 more sources

Mouse models of myeloproliferative Neoplasms: JAK of all grades. (Review) [PDF]

open access: yes, 2011
In 2005, several groups identified a single gain-of-function point mutation in the JAK2 kinase that was present in the majority of patients with myeloproliferative neoplasms (MPNs).
Li, J.   +7 more
core   +2 more sources

LNK (SH2B3): paradoxical effects in ovarian cancer. [PDF]

open access: yes, 2015
LNK (SH2B3) is an adaptor protein studied extensively in normal and malignant hematopoietic cells. In these cells, it downregulates activated tyrosine kinases at the cell surface resulting in an antiproliferative effect. To date, no studies have examined
Chien, W   +16 more
core   +2 more sources

STAT1 activation in association with JAK2 exon 12 mutations [PDF]

open access: yes, 2015
La inclusión de la perspectiva de género en la actividad jurisdiccional es una demanda sostenida de los colectivos feministas y de mujeres, dado que las sentencias tienen un poder performativo y envían un mensaje a la sociedad: “[…] tienen un poder ...
Godfrey, A.L.   +33 more
core   +4 more sources

Casitas B-lineage lymphoma linker helix mutations found in myeloproliferative neoplasms affect conformation [PDF]

open access: yes, 2016
Background: Casitas B-lineage lymphoma (Cbl or c-Cbl) is a RING ubiquitin ligase that negatively regulates protein tyrosine kinase (PTK) signalling. Phosphorylation of a conserved residue (Tyr371) on the linker helix region (LHR) between the substrate ...
Ahmed, Syed Feroj   +7 more
core   +2 more sources

Splanchnic vein thrombosis in myeloproliferative neoplasms: Pathophysiology and molecular mechanisms of disease [PDF]

open access: yes, 2016
Myeloproliferative neoplasms (MPNs) are the most common underlying prothrombotic disorder found in patients with splanchnic vein thrombosis (SVT). Clinical risk factors for MPN-associated SVTs include younger age, female sex, concomitant hypercoagulable ...
How, Joan, Oh, Stephen T, Zhou, Amy
core   +2 more sources

Home - About - Disclaimer - Privacy